Sonablate^® HIFU is approved in more than 50 countries worldwide and was the first focused ultrasound device to be FDA-cleared in the U.S. for the ablation of prostate tissue. This innovative solution for prostate diseases has allowed Sonablate^® HIFU to become the industry leader in focal therapy. Caution: Federal (USA) law restricts this device to sale by or on the order of a physician.
‍
Sonablate is a registered trademark of Sonablate Corp. © 2024 Sonablate Corp. All rights reserved.